12 news items
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
ZLAB
22 May 24
(Humabody®) targeting the IL-17 cytokine. Emphasizing its unique approach, ZL-1102 is being developed as a topical treatment for mild
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
ZLAB
20 May 24
of Acinetobacter baumannii-calcoaceticus complex – the first such FDA-approved pathogen-targeted therapy
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA
ZLAB
12 May 24
AUGTYRO (repotrectinib) is a next-generation tyrosine kinase inhibitor targeting
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
ABNB
ADV
AGS
9 May 24
estimates. Also, Needham maintained a Buy rating on the stock and lowered its price target from $17 to $12.
Syra Health Corp
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
CRDF
JNJ
NTBL
9 May 24
. As researchers gain a better understanding of the different types of pancreatic cancer, they are developing more targeted treatments that are more likely
7tr26bogbleezoazjh27v8m70 zgmn034qkxa3s
ZLAB
2 Apr 24
antibody-drug conjugate (ADC) within the Zai Lab pipeline that targets the Delta-like ligand 3 (DLL3
3q76tf11y28tp6ww4xcloco4g640fv2kua
BMY
ZLAB
1 Apr 24
profile.
The FDA granted accelerated approval for Krazati as a targeted treatment for patients with KRASG12C-mutated locally advanced
iet2si7mt83l8a2sd60icutnlqk6grmmzjath92eunkh6po4
NVCR
ZLAB
27 Mar 24
systemic therapy for their NSCLC at the discretion of their treating physician. Patients with known tumor mutations for which targeted agents
z220pu6f1z77hs95y0ha3tm42xv5n ej1iawf596b0cy3jim98zg
NVCR
ZLAB
27 Mar 24
with known tumor mutations for which targeted agents are available were excluded from the trial
v7wnue51fk72lrw1vygwzmitsx9a1r9ta5w3jn 0cfhzbq8d0h61skkeq8
ZLAB
14 Mar 24
ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target in small cell lung cancer and other DLL3+ solid tumors
a78z79g8az4yb3hj k2pphg0pfojzs8
ZLAB
13 Mar 24
ZL-1310 is an innovative ADC targeting DLL3
zxcbd5icvp0rlhtv5m0ib4fn 9hpyq8ql2raba6mslw3d89v7
ZLAB
29 Feb 24
Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and lowers the price target from $123 to $66.
- Prev
- 1
- Next